Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

Inaugural LATAM Awards

Highlights from the NCI Post-Treatment Surveillance Workshop

Top Science in Lung Cancer Featured at WCLC 2018

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

WCLC Plenary Symposia to Include Practice-Changing Research Presentations

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

The Long Road Home